Capital Fund Management (CFM)
HZNP

Capital Fund Management (CFM)’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Capital Fund Management (CFM)’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-26,500
Closed -$439K – 2423
2018
Q2 		$439K Buy
+26,500
New +$404K ﹤0.01% 1646

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Capital Fund Management (CFM)'s HZNP Position: Q2 2019 in Review

Capital Fund Management (CFM) sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2019, closing a stake of 126,942 shares — an estimated $3.35M sold.

Capital Fund Management (CFM) first reported a position in HZNP in Q4 2014 and held it in 17 quarters. The position peaked at $12.1M in Q1 2017. 272 funds tracked by Wall St. Rank hold HZNP as of Q2 2019.

  • Capital Fund Management (CFM) reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2019 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 126,942 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2019, an estimated $3.35M.
  • Capital Fund Management (CFM) first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2014 and held it in 17 quarters.
  • Capital Fund Management (CFM)'s Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $12.1M in Q1 2017.
  • 272 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2019.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2019, filed 12 Aug 2019.